Jan N. Lessem
Directeur Technique/Scientifique/R&D chez Orthocon, Inc.
Profil
Jan N.
Lessem is a professional with a career history that includes several positions in the medical and pharmaceutical industries.
Currently, he is the Head of Clinical & Medical Affairs at Orthocon, Inc. Prior to this, he held positions as Chief Medical Officer & VP-Clinical Research at OraPharma, Inc., Chief Medical Officer & Vice President at Shire Regenerative Medicine, Inc., and Chief Medical Officer & Executive Vice President at CombinatoRx, Inc. He also worked as a Director of Clinical Cardiovascular Research at Merck & Co., Inc. and as a Medical Director at Takeda America Research & Development Center, Inc. Dr. Lessem received his graduate and doctorate degrees from the University of Lund.
Postes actifs de Jan N. Lessem
| Sociétés | Poste | Début |
|---|---|---|
Orthocon, Inc.
 Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | Directeur Technique/Scientifique/R&D | 01/01/2012 |
Anciens postes connus de Jan N. Lessem
| Sociétés | Poste | Fin |
|---|---|---|
CombinatoRx, Inc.
 CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Directeur Technique/Scientifique/R&D | 31/01/2007 |
OraPharma, Inc.
 OraPharma, Inc. Pharmaceuticals: MajorHealth Technology OraPharma, Inc. develops and produces drugs for oral diseases. It offers a suite of products to address a range of patient concerns from the foundation of gums, bone, and teeth to the aesthetics of a whiter smile. The company's products include ARESTIN Microspheres, a locally administered antibiotic indicated as an adjunct to scaling and root planning procedures for the reduction of pocket depth in patients with adult periodontitis; and ONSET Approach, a unique delivery system of locally buffered anesthesia that provides faster onset of anesthesia and a comfortable injection. The company was founded in 1996 and is headquartered in Horsham, PA. | Directeur Technique/Scientifique/R&D | 01/01/2003 |
| MERCK & CO., INC. | Corporate Officer/Principal | 28/02/2011 |
| Takeda America Research & Development Center, Inc. | Directeur Technique/Scientifique/R&D | - |
Shire Regenerative Medicine, Inc.
 Shire Regenerative Medicine, Inc. BiotechnologyHealth Technology Shire Regenerative Medicine, Inc. develops and commercializes living cell therapies. It manufactures and markets dermagraft, a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body's natural healing process. The company was founded in 2004 and is headquartered in Westport, CT. | Directeur Technique/Scientifique/R&D | - |
Formation de Jan N. Lessem
| University of Lund | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
OraPharma, Inc.
OraPharma, Inc. Pharmaceuticals: MajorHealth Technology OraPharma, Inc. develops and produces drugs for oral diseases. It offers a suite of products to address a range of patient concerns from the foundation of gums, bone, and teeth to the aesthetics of a whiter smile. The company's products include ARESTIN Microspheres, a locally administered antibiotic indicated as an adjunct to scaling and root planning procedures for the reduction of pocket depth in patients with adult periodontitis; and ONSET Approach, a unique delivery system of locally buffered anesthesia that provides faster onset of anesthesia and a comfortable injection. The company was founded in 1996 and is headquartered in Horsham, PA. | Health Technology |
Shire Regenerative Medicine, Inc.
Shire Regenerative Medicine, Inc. BiotechnologyHealth Technology Shire Regenerative Medicine, Inc. develops and commercializes living cell therapies. It manufactures and markets dermagraft, a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body's natural healing process. The company was founded in 2004 and is headquartered in Westport, CT. | Health Technology |
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Health Technology |
Orthocon, Inc.
Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | Health Technology |
| Takeda America Research & Development Center, Inc. |
